Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of immuno-oncology, leveraging cutting-edge stem cell-based platforms to revolutionize cancer treatment. Headquartered in San Diego, California, Calidi specializes in developing proprietary technologies that utilize potent allogeneic stem cells to deliver and enhance the efficacy of oncolytic viruses, targeting a range of oncology indications, including high-grade gliomas and solid tumors.
Innovative Stem Cell-Based Platforms
Calidi's core innovation lies in its unique, off-the-shelf, universal cell-based delivery platforms. These platforms are designed to protect, amplify, and potentiate oncolytic viruses, significantly improving therapeutic outcomes while ensuring patient safety. The company's dual approach includes localized therapies, such as its CLD-101 platform for high-grade gliomas, and systemic therapies, like RTNova, which targets metastatic cancers. By addressing both localized and advanced-stage cancers, Calidi aims to overcome critical challenges in oncology, including the rapid immune clearance of virotherapies and limited therapeutic targeting.
Clinical and Preclinical Programs
Calidi is advancing a robust pipeline of clinical-stage and preclinical candidates. Its CLD-101 platform, utilizing neural stem cells loaded with oncolytic adenoviruses, is undergoing Phase 1b/2 trials for high-grade glioma at Northwestern University. Early studies have demonstrated safety, feasibility, and promising anti-tumor immune responses, paving the way for transformative outcomes in brain cancer treatment. The RTNova platform, on the other hand, represents a breakthrough in systemic virotherapy, leveraging extracellular enveloped viruses (EEVs) to target multiple metastatic tumor sites while avoiding rapid immune clearance.
Regenerative Medicine and Beyond
In addition to oncology, Calidi is exploring the potential of its stem cell technologies in regenerative medicine through its Nova Cell subsidiary. This strategic expansion taps into the growing global demand for stem cell therapies, targeting applications in cosmetics, orthopedics, autoimmune diseases, and more. With a proprietary cell expansion method and specialized media, Calidi's approach offers significant scalability advantages over conventional mesenchymal stem cell lines.
Position in the Competitive Landscape
Operating within the rapidly evolving biotech industry, Calidi differentiates itself through its proprietary stem cell-based delivery platforms and dual therapeutic strategies. While competitors in the immuno-oncology space also focus on oncolytic virotherapies, Calidi's integration of stem cell technology enhances the safety, efficacy, and scalability of its treatments, positioning it as a potential leader in this niche. The company's strong intellectual property portfolio and strategic collaborations further bolster its competitive edge.
Commitment to Innovation and Patient Outcomes
Calidi Biotherapeutics is committed to addressing some of the most challenging cancers and unmet medical needs. Through its innovative platforms and ongoing clinical trials, the company aims to redefine how cancer is treated, offering hope to patients with limited therapeutic options. By combining scientific rigor with a focus on scalability and safety, Calidi is poised to make significant contributions to the fields of oncology and regenerative medicine.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm focused on antitumor virotherapies, has appointed Dr. George E. Peoples to its Board of Directors, effective July 1, 2024. Dr. Peoples is renowned in cancer immunotherapy, with over 20 years of experience in developing and testing cancer vaccines. He is the Founder and Director of the Cancer Vaccine Development Program and has held significant roles in both military and clinical settings. His expertise is expected to aid Calidi in advancing their cancer immunotherapies into later-stage clinical trials. CEO Allan Camaisa highlighted Dr. Peoples’ pioneering work and extensive experience as key assets for the company’s growth.
Calidi Biotherapeutics, a clinical-stage biotechnology firm, is hosting a live investor webinar on June 13, 2024, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature insights from the Chief Business Officer, Stephen Thesing, and CFO, Andrew Jackson. Calidi focuses on developing next-generation immunotherapies, specializing in oncolytic virotherapy (OV) to target and eliminate cancer cells. Their proprietary cell-based technologies protect OVs from immune system elimination and modify the tumor microenvironment for enhanced therapeutic outcomes. The webinar will also include a live Q&A session. Register here: Webinar Registration.
Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors. RTNova leverages a vaccinia virus enveloped by a human cell membrane to evade immunity and enhance therapeutic functions. SIGA will supply TPOXX, an antiviral agent against vaccinia virus, to support RTNova's development. This collaboration aims to create a universal treatment for all tumor types and will initially focus on lung cancer and metastatic solid tumors. RTNova's novel approach allows for easy administration and a broader patient reach. The partnership offers a safety mechanism for clinical trials, ensuring better regulatory compliance and patient safety.
Calidi Biotherapeutics presented significant updates at the 2024 ASCO Annual Meeting, focusing on their NeuroNova (CLD-101), RTNova (CLD-400), and SuperNova (CLD-201) programs. CLD-101's Phase 1 trial is progressing, with safety and feasibility confirmed for up to four weekly doses in patients with high-grade gliomas. Preclinical data on RTNova showed its ability to target and reach tumors systemically, while SuperNova (CLD-201) demonstrated promising non-clinical results, with no adverse toxicity and effective tumor volume reduction. These findings underscore Calidi's innovative approach to antitumor virotherapy and reinforce their commitment to advancing targeted immunotherapies.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a definitive agreement for the immediate exercise of certain outstanding Series B and C warrants. This move allows the purchase of up to 10,698,000 shares of Calidi’s common stock at a reduced price of $0.20 per share, generating gross proceeds of approximately $2.1 million.
The funds will be used to support Calidi’s clinical and pre-clinical programs and cover operating expenses. In exchange, Calidi will issue new unregistered warrants with an exercise price of $0.30 per share, exercisable upon shareholder approval, and expiring five and a half years from the issuance date.
This offering is expected to close by June 3, 2024, and is facilitated by Ladenburg Thalmann & Co as the exclusive placement agent. The new warrants will be offered in a private placement under Section 4(a)(2) of the Securities Act of 1933.
ASP Isotopes (Nasdaq:ASPI) and Calidi Biotherapeutics (NYSE American:CLDI) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing May 25 at 7 p.m. ET. ASP Isotopes CEO Paul Mann will discuss the company's advancements in nuclear medicine and green nuclear energy, emphasizing its strong financial position with no long-term debt and significant cash reserves. H.C. Wainwright reaffirmed its buy rating, raising the price target to $5.50. Calidi Biotherapeutics CEO Allan Camaisa will highlight their cutting-edge oncolytic virotherapy (OV) treatments for cancer, showcasing promising initial study results and innovative IV-based technology for enhanced treatment efficacy.
Calidi Biotherapeutics (NYSE American: CLDI) and Unusual Machines (NYSE American: UMAC) will feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing on May 18 at 7 p.m. ET.
Calidi Biotherapeutics, led by CEO Allan Camaisa, specializes in oncolytic virotherapy (OV) for cancer treatment. Their engineered viruses target cancer cells and bolster the immune system, showing promising initial study results. Calidi's unique technologies enhance OV efficacy and treatment potential.
Unusual Machines, headed by CEO Allan Evans, focuses on the drone industry. The company is growing through strategic acquisitions and development of FPV products, aiming to serve various industries like consumer, public safety, and drone delivery. Subsidiaries Fat Shark and Rotor Riot lead in FPV experiences, positioning the company for long-term success.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm, reported its Q1 2024 financial results and business developments. Key highlights include three upcoming posters at the 2024 ASCO Annual Meeting, featuring an update from the ongoing Phase 1 trial of CLD-101 for recurrent high-grade glioma.
Calidi also presented new data on its immunotherapies at the AACR Annual Meeting and unveiled the RTNova systemic delivery platform targeting multiple tumor types. The company completed a $6.1 million public offering, strengthening its balance sheet amid ongoing capital-raising efforts and cost-cutting measures to advance its pipeline.
Financially, Calidi reported a net loss of $7.2 million ($0.20 per share) for Q1 2024, a slight increase from $6.5 million ($0.75 per share) in Q1 2023. R&D expenses increased marginally to $2.7 million, while G&A expenses grew to $4.0 million from $2.8 million. The company ended Q1 2024 with $1.2 million in cash and $0.2 million in restricted cash.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced the acceptance of three abstracts for presentation at the 2024 ASCO Annual Meeting. The abstracts focus on their innovative programs for the treatment of high-grade glioma and solid tumors. Calidi will present updates on their CLD-101, RTNova, and CLD-201 programs, showcasing their cutting-edge therapeutic candidates.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
What does Calidi Biotherapeutics specialize in?
What is unique about Calidi's technology?
What are Calidi's key clinical programs?
How does Calidi address metastatic cancers?
What other applications does Calidi's technology have?
Where is Calidi Biotherapeutics headquartered?
What challenges does Calidi face in its market?
How does Calidi's technology improve patient safety?
